AbbVie Inc. Files 8-K on Financials

Ticker: ABBV · Form: 8-K · Filed: 2025-04-25T00:00:00.000Z

Sentiment: neutral

Topics: financial-results, 8-k

Related Tickers: ABBV

TL;DR

ABBV filed an 8-K on 4/25/25 detailing financial results. Check it out.

AI Summary

AbbVie Inc. filed an 8-K on April 25, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's business. AbbVie Inc. is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This 8-K filing provides crucial updates on AbbVie's financial performance and condition, which is essential for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting financial results and does not indicate any unusual risks or events.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for AbbVie Inc.?

The primary purpose of this 8-K filing is to report on AbbVie Inc.'s Results of Operations and Financial Condition, and it includes Financial Statements and Exhibits.

On what date was this 8-K report filed or as of what date is it effective?

The report is dated April 25, 2025, and is the date of the earliest event reported.

In which U.S. state is AbbVie Inc. incorporated?

AbbVie Inc. is incorporated in Delaware.

What is AbbVie Inc.'s Employer Identification Number (EIN)?

AbbVie Inc.'s EIN is 32-0375147.

What is AbbVie Inc.'s fiscal year end?

AbbVie Inc.'s fiscal year ends on December 31.

From the Filing

0001551152-25-000026.txt : 20250425 0001551152-25-000026.hdr.sgml : 20250425 20250425074822 ACCESSION NUMBER: 0001551152-25-000026 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250425 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250425 DATE AS OF CHANGE: 20250425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 25870012 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20250425.htm 8-K abbv-20250425 0001551152 false 0001551152 2025-04-25 2025-04-25 0001551152 exch:XNYS us-gaap:CommonStockMember 2025-04-25 2025-04-25 0001551152 exch:XNYS abbv:Sec0.750SeniorNotesDue2027Member 2025-04-25 2025-04-25 0001551152 exch:XNYS abbv:Sec2.125SeniorNotesdue2028Member 2025-04-25 2025-04-25 0001551152 exch:XNYS abbv:Sec2625SeniorNotesDue2028Member 2025-04-25 2025-04-25 0001551152 exch:XNYS abbv:Sec2125SeniorNotesDue2029Member 2025-04-25 2025-04-25 0001551152 exch:XNYS abbv:Sec1.250SeniorNotesdue2031Member 2025-04-25 2025-04-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  _____________________________________________________ FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): April 25, 2025   ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware   001-35565   32-0375147 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)  _____________________________________________________ 1 North Waukegan Road North Chicago ,  Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐                       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange NYSE Texas 0.750% Senior Notes due 2027 ABBV27 New York Stock Exchange 2.125% Senior Notes due 2028 ABBV28 New York Stock Exchange 2.625% Senior Notes due 2028 ABBV28B New York Stock Exchange 2.125% Senior Notes due 2029 ABBV29 New Yor

View on Read The Filing